Activating the body’s innate healing ability to treat degenerative disease

Learn about our lead candidate, FX-322, a potential regenerative treatment for sensorineural hearing loss

Learn More

Working to Transform the Treatment of Hearing Loss

Frequency’s lead product candidate, FX-322, is designed to activate progenitor cells in the ear to regenerate damaged auditory cells and improve hearing function. FX-322 targets a condition known as sensorineural hearing loss, or SNHL, which impacts more than 90 percent of all people with hearing loss.

FX-322 aims to repair the underlying cause of SNHL and improve overall sound clarity and intelligibility, moving beyond today’s standard of care which focuses on sound amplification.

Learn More

Our Progenitor Cell Activation Approach

Frequency is a leader in the discovery and development of therapeutics that activate progenitor cells for the treatment of degenerative diseases.

Our small molecule approach aims to activate progenitor cells in specific damaged or injured tissues throughout the body in order to create healthy functional tissues and organs.

Learn More


October 10, 2019

Frequency Therapeutics Commences Dosing in its Phase 2a Study of FX-322 for Sensorineural Hearing Loss; FDA Grants FX-322 Fast Track Designation

Read More

October 2, 2019

Frequency Therapeutics Announces Pricing of Initial Public Offering

Read More

August 22, 2019

Frequency Therapeutics Expands Leadership Team

Read More

Join Our Team

Learn more about Frequency, our team and culture, and opportunities to grow your career.

Learn More